feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Alzecure: Reports Positive Phase I “MAD” results with ACD856
Redeye endorses the positive outcome from Alzecure’s phase I “MAD” study with drug candidate ACD856 and slightly raise our base case.
FT
Fredrik Thor
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans